ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 125,45
-0,07%
Dow Jones
39 056,39
0,44%
DAX
18 549,19
0,33%
Brent Oil
83,995
0,52%
Bitcoin
60 983,52
-0,33%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) Actualités

ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ASND
DateHeureSourceTitreSymboleSociété
02/05/202422h01GlobeNewswire Inc.Ascendis Pharma Reports First Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
25/04/202422h46GlobeNewswire Inc.Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024NASDAQ:ASNDAscendis Pharma AS
24/04/202414h30GlobeNewswire Inc.United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
07/03/202417h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
04/03/202414h30GlobeNewswire Inc.Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ASNDAscendis Pharma AS
14/02/202422h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
14/02/202415h17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ASNDAscendis Pharma AS
07/02/202422h15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:ASNDAscendis Pharma AS
07/02/202422h01GlobeNewswire Inc.Ascendis Pharma Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:ASNDAscendis Pharma AS
07/02/202414h30GlobeNewswire Inc.Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ASNDAscendis Pharma AS
31/01/202422h15GlobeNewswire Inc.Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024NASDAQ:ASNDAscendis Pharma AS
31/01/202422h01GlobeNewswire Inc.Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
29/01/202414h30GlobeNewswire Inc.New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External InvestorsNASDAQ:ASNDAscendis Pharma AS
08/01/202414h20GlobeNewswire Inc.Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries NASDAQ:ASNDAscendis Pharma AS
07/01/202423h45GlobeNewswire Inc.Ascendis Pharma Introduces Vision 2030NASDAQ:ASNDAscendis Pharma AS
07/01/202420h00PR Newswire (US)Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countriesNASDAQ:ASNDAscendis Pharma AS
28/12/202322h15GlobeNewswire Inc.Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
20/12/202314h30GlobeNewswire Inc.Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/weekNASDAQ:ASNDAscendis Pharma AS
19/12/202314h30GlobeNewswire Inc.TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
11/12/202314h30GlobeNewswire Inc.FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
29/11/202310h30GlobeNewswire Inc.Ascendis Pharma Announces Strategic Partnership with Teijin Limited in JapanNASDAQ:ASNDAscendis Pharma AS
20/11/202314h00GlobeNewswire Inc.Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
15/11/202314h00GlobeNewswire Inc.Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDANASDAQ:ASNDAscendis Pharma AS
07/11/202322h01GlobeNewswire Inc.Ascendis Pharma Reports Third Quarter 2023 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
31/10/202313h30GlobeNewswire Inc.Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA ResubmissionNASDAQ:ASNDAscendis Pharma AS
26/10/202314h30GlobeNewswire Inc.Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023NASDAQ:ASNDAscendis Pharma AS
16/10/202322h01GlobeNewswire Inc.Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023NASDAQ:ASNDAscendis Pharma AS
02/10/202314h00GlobeNewswire Inc.Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual MeetingNASDAQ:ASNDAscendis Pharma AS
23/09/202313h00GlobeNewswire Inc.Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
15/09/202314h00GlobeNewswire Inc.Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
 Showing the most relevant articles for your search:NASDAQ:ASND

Dernières Valeurs Consultées

EU
DG
Vinci
EU
SGO
Cie de SaintGobain
EU
MC
Lvmh Moet Hennessy Louis...
EU
AF
Air FranceKLM
EU
HO
Thales
COIN
BTCUSD
Bitcoin
EU
AI
Air Liquide
EU
CAP
Capgemini
NASDAQ
NVDA
NVIDIA
EU
VIV
Vivendi
EU
CS
Axa
NYSE
DIS
Walt Disney
EU
RNO
Renault
EU
GLE
Societe Generale
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés